Johnson & Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an...
Drug
Tasly Pharma Gains NMPA Green Light for CAR-T Therapy Clinical Study in Recurrent Glioblastoma
China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received approval from...
CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin
China-based CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294) has announced that it has received...
Juventas Cell Therapy Secures China Clinical Trial Approval for Inaticabtagene Autoleucel in AIHA
Chinese firm Juventas Cell Therapy Ltd has obtained tacit clinical trial approval in China for...
Belief BioMed and Takeda Win NMPA Approval for China’s First Hemophilia B Gene Therapy
China-based gene therapy specialist Belief BioMed Inc. and Takeda’s (NYSE: TAK, TYO: 4502) China unit...
Zai Lab’s Partner argenx Secures FDA Approval for Vygart Hytrulo Prefilled Syringe in gMG and CIDP
China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) and its Dutch partner argenx SE (NASDAQ:...
Jemincare Group Announces NMPA Approval of Generic Clenil for Asthma Treatment
China-based Jiangxi Jemincare Group has announced that it has received marketing approval from the National...
Bayer’s Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors
Germany-based Bayer (ETR: BAYN) announced that it has received full approval from the US Food...
Luye Pharma Launches Rotigotine Luye in UK for Parkinson’s and Restless Leg Syndrome
China-based Luye Pharma Group (HKG: 2186) announced the market launch of Rotigotine Luye in the...
CK Life Sciences Reports Promising Preclinical Results for TROP2-Targeted Cancer Vaccine
China-based CK Life Sciences (HKG: 0775) has announced positive early results from preclinical studies of...
Kangtai Biological’s Pentavalent Rotavirus Vaccine Enters Phase III Trials
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) announced the enrollment of the first patient...
Zelgen Biopharma’s ZG005 Approved for Gastrointestinal Tumor Trials in China
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received approval from China’s...
HemaCell’s XJ-MK-002 Gains FDA Orphan Drug Designation for Giant Platelet Syndrome
China-based Suzhou Xueji Biotechnology Co., Ltd (HemaCell), a pioneer in platelet regeneration-focused cell therapy, announced...
IVIEW Therapeutics’ IVIEW-1201 Gains FDA Orphan Drug Designation for Fungal Keratitis
China-based IVIEW Therapeutics Inc. announced that it has received Orphan Drug Designation (ODD) from the...
Hansoh Pharma’s Ibrexafungerp Approved for Vulvovaginal Candidiasis in China
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced this week that it has received...
Hengrui Pharmaceuticals’ Ivarmacitinib Approved for Atopic Dermatitis
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...
Beijing StarMab’s SM2275 Receives FDA IND Approval for Dual-Target Cancer Therapy
China-based Beijing StarMab BioMed Technology, Ltd. announced that it has received Investigational New Drug (IND)...
B. Braun’s DUPLEX System Approved by FDA for Piperacillin and Tazobactam
B. Braun Medical Inc., a US-based healthcare company, announced that the U.S. Food and Drug...
Sino Biopharma’s TQB3019 Gains NMPA Approval for Hematological Malignancies
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the...
Simcere Pharmaceutical Gains NMPA Approval for FGFR2b-Targeted ADC SIM0686
China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the National...